Business, energy, technology, markets and global industry news from Business News Today

Viatris Inc.

PharmaDeviceNews Viatris Inc.
Representative image of a weekly contraceptive patch being assessed in a clinical setting, reflecting Viatris Inc.’s MR-100A-01 data update as the FDA review places low-dose estrogen transdermal contraception back in focus.
Pharma & Biotech

Can adhesion and lower estrogen dosing make Viatris’s contraceptive patch stand out?

Viatris has patch expertise. FDA scrutiny now decides whether lower estrogen and adhesion data can turn MR-100A-01 into a real growth lever.

Read More